The largest database of trusted experimental protocols

Ketorolac

Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic, anti-inflammatory, and antipyretic properties.
It is commonly used for the mangement of moderate to severe pain, including postoperative pain, cancer pain, and pain associated with musculoskeletal conditions.
Ketorolac works by inhibiting the cyclooxygenase (COX) enzymes, which are involved in the production of prostaglandins that contribute to inflammation and pain.
Its efficacy and safety have been extensively studied, and it is available in various formulations, including oral, parenteral, and topical.
Researchers can optimize their Ketorolac studies using PubCompare.ai, an AI-driven platform that helps identify the best protocols and products from the literature, pre-prints, and patents, while providing detailed comparisons to enhance reproducibilty and accuacy.

Most cited protocols related to «Ketorolac»

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2015
Acclimatization Analgesics Animals Antibiotics Astrocytes Cannula Catheterization Catheters Cloning Vectors Condoms Diffusion Environment, Controlled Heparin Jugular Vein Ketamine Ketorolac Males Nucleus Accumbens Operative Surgical Procedures Plasmids Rats, Sprague-Dawley Rivers Self Administration Silastic Timentin Virus Xylazine
To study the rate and extend of Ketorolac that diffused through the skin, an ex vivo permeation assay was performed. The experiment was conducted as designed for the release assay except that 500-µm dermatomed frozen skin was used instead of synthetic membrane (n = 6). The skin was thawed at room temperature, and skin discs were punched and mounted on the Franz cell (0.64 cm2 of diffusion area) with the Stratum Corneum facing up to the donor compartment and the dermis in contact with the receptor fluid [35 (link)]. Hydrogel (200 mg) was applied to the skin, and samples (300 µL) were collected at the time intervals: 0, 3, 6, 8, 10, 19.75, 20.75, and 24 h and stored at −20 °C until sample analysis by HPLC was carried out.
Full text: Click here
Publication 2021
Biological Assay Cells Dermis Diffusion Freezing High-Performance Liquid Chromatographies Hydrogels Ketorolac Skin Tissue, Membrane Tissue Donors
The injections of virus (PRSx8-hChR2 (H134R)-mCherry or PRSx8-Allato-EGFP) were made while the rats (Sprague-Dawley, males, weight: 219–282gm) were anaesthetized with a mixture of ketamine (75mg/kg), xylazine (5mg/kg) and acepromazine (1mg/kg) administered i.m. Surgery used standard aseptic methods, and after surgery, the rats were treated with the antibiotic ampicillin (100mg/kg, i.m.) and the analgesic ketorolac (0.6mg/kg, i.p.). The lentivirus was delivered into the RTN by controlled pressure injection (60 PSI, 3–8 ms pulses) using glass pipettes pulled to an external tip diameter of 25μm. These pipettes (resistance: 6–12Ω) allowed the recording of antidromic field potentials that were elicited by stimulating the mandibular branch of the facial nerve and were used to direct the electrode tip to the desired sites under the caudal pole of the facial nucleus. Injections were made unilaterally at 2 and, more rarely 3 different rostro-caudally aligned sites separated by 200 (3 injections) or 300μm (2 injections) for a total volume of 400 nl. In a subset of animals (n=5), we also injected anti-dopamine-β-hydroxylase conjugated to saporin (antiDβH-sap; Advanced Targeting Systems, San Diego, CA) at 0.22 μg per μl bilaterally (4 sites total, 100nl per site) into the region of the lateral horn of the second thoracic segment (1.0–1.2mm lateral of midline, 1mm below lateral sulcus) in order to destroy the C1 neurons that project to the spinal cord. Animals were maintained for no less than 3 weeks before they were used in physiological experiments. The surgical procedures and virus injections produced no observable behavioral or respiratory effects and these rats gained weight normally.
Publication 2009
Acepromazine Ampicillin Analgesics Animals Antibiotics Asepsis Chest Dopamine beta Monooxygenase Face Facial Nerves Facial Nucleus Horns Ketamine Ketorolac Lentivirus Males Mandible Mandibular Nerves Neurons Operative Surgical Procedures physiology Pressure Pulses Rattus Respiratory Rate Saporins Spinal Cord Virus Xylazine
Individual covariates [age, sex, race and morphine dose in mg/kg POD1 and 2, preoperative anxiety score (VAS), preoperative pain score, duration of surgery, vertebral levels fused, propofol and remifentanil doses used during surgery (per kg), use of intravenous acetaminophen/ketorolac (Yes/No), diazepam doses (mg/kg), and sequential scores for CASI, PCS-C, PCS-P and PPH] were analysed to identify those associated with AUC using simple linear regression models. Similarly, the same factors as well as AUC were evaluated to identify factors associated with CP and PP using univariate logistic regression models; those associated at a p < 0.10 were entered into multivariable models and stepwise selection used to derive a final model for each outcome where only variables with a p < 0.05 were retained (Bursac et al., 2008 (link)). Correlation between two continuous variables was examined using either Spearman’s or Pearson’s correlation coefficient as appropriate. Linear trajectories of pain scores were estimated for different combinations of PP and CP outcomes for subjects who had both CP and PP outcomes reported. (i.e. CP = No, PP = No; CP = No, PP = Yes; CP = Yes, PP = No; and CP = Yes, PP = Yes).
Power calculation was done using PASS (Power and Sample Size,© 2008, Kaysville, Utah). Assuming an incidence of our main binary outcome (Y = persistent pain) to be 20–30% (based on prior studies which show an incidence of 22% (Page et al. 2013b (link)) to 29.5% (Landman et al., 2011 (link); Cudilo et al., 2014 ), and our pilot data), for a logistic regression of (Y) on a continuous, normally distributed variable (X). With a sample size of 100, we have 80% power to detect an effect size of 2–2.7 at a 0.05 significance level (α = 0.05). This assumes X’s multiple correlations with covariates already in the model is 0.5. With lower multiple correlation between X and other covariates, we can achieve the same power with less samples, or detect a smaller effect size. The sample size required increases to 118 assuming an expected loss to follow-up of 15%.
Publication 2017
Acetaminophen AH 22 Anxiety Diazepam Ketorolac Morphine Operative Surgical Procedures Pain Propofol Remifentanil Vertebra
Neuropathic mice, on or around day 15, were randomly assigned to receive i.p. gabapentin (100 mg/kg), etanercept (20, 40 mg/kg), ketorolac (15 mg/kg), morphine (1, 3 and 10 mg/kg), or saline (vehicle). In another group of animals, we undertook a pretreatment regimen of etanercept (40 mg/kg) or saline delivered just before the first cisplatin injection (n = 4–6 per group).
Publication 2012
Animals Cisplatin Etanercept Gabapentin Ketorolac Mice, House Morphine Saline Solution Treatment Protocols

Most recents protocols related to «Ketorolac»

In Yuan et al study,[29 (link)] patients received standardized general anesthesia and basic analgesic protocol. Intraoperatively, all patients received general anesthesia which was induced by sufentanil 0.5 μg/kg, midazolam 0.04 mg/kg, propofol 1 to 2 mg/kg, and Cisatracurium 2 μg/kg intravenously, followed by continuous intravenous infusion of remifentanil 0.1 to 0.3 μg/(kg·min), propofol 2 to 5 mg/(kg·hr) and inhalation of sevoflurane to maintain anesthesia. Since postoperative day 1, the protocol of oral celecoxib restarted till postoperative 3 weeks when the patients came back to the hospital for taking out the stitches. In Yadeau et al 2016 study,[6 (link)] patients received a standardized anesthetic and multimodal analgesic protocol. In Yadeau et al 2022 study,[28 (link)] patients received a standard intraoperative and postoperative multimodal anesthetic protocol: a spinal-epidural (subarachnoid mepivacaine, 45–60 mg); adductor canal block (ultrasound-guided; 15 cc bupivacaine, 0.25%, with 2 mg preservative-free dexamethasone). For postoperative pain management, patients were scheduled to receive the study medication once daily for 14 days; 4 doses of 1000 mg IV acetaminophen every 6 hours followed by 1000 mg oral acetaminophen every 8 hours; 4 doses of 15 mg IV ketorolac followed by 15 mg meloxicam every 24 hours; and 5 to 10 mg oral oxycodone was given as needed for pain. Patients could have pain medications adjusted as indicated. In Koh et al study,[12 (link)] all patients had a postoperative intravenous patient-controlled anesthesia (PCA) pump that administered 1 mL of a 100-mL mixture containing 2000 mg of fentanyl on demand. In Kim et al study,[27 ] all patients received intravenous PCA encompassing delivery of 1 mL of a 100 mL solution containing 2000 µg of fentanyl postoperatively. In Ho et al study,[26 (link)] patients were routinely offered a single shot spinal anesthesia consisting of an intrathecal dose of bupivacaine 10 to 12.5 mg with fentanyl 10 mg. After surgery, pain treatment consisted of PCA with intravenous injection of morphine. The settings were 1 mg bolus, 5 minutes lockout time, and a maximum hourly limit of 8 mg. All patients were also given acetaminophen 1 g 6 hourly.
Publication 2023
Acetaminophen Analgesics Anesthesia Anesthesia, Intravenous Anesthetics Bupivacaine Cardiac Arrest Celecoxib cisatracurium Dexamethasone Fentanyl General Anesthesia Inhalation Intravenous Infusion Ketorolac Management, Pain Meloxicam Mepivacaine Midazolam Morphine Multimodal Imaging Obstetric Delivery Operative Surgical Procedures Oxycodone Pain Pain, Postoperative Patients Pharmaceutical Preparations Pharmaceutical Preservatives Propofol Pulp Canals Remifentanil Sevoflurane Spinal Anesthesia Subarachnoid Space Sufentanil Ultrasonography
This study was conducted after obtaining approval from the institutional review board of our hospital (YUMC-2019-09-052) and informed consent from the patients. This study was registered in ClinicalTrials.gov (registration number: NCT05320783). Using a prospective, randomized, controlled clinical protocol, 82 patients (aged 20–65 years), American society of anesthesiologists physical status I and II, undergoing gynecological laparoscopic surgery were included in the study. The exclusion criteria were as follows: any hearing impairment, known psychiatric or memory disorder, alcohol or analgesic abuse, and inability to complete the questionnaires.
Patients were allocated to the music intervention group (group M, n = 41) or control group (group C, n = 41) using a random number sequence, which ensured adequate concealment. The patients did not receive any premedication. Routine monitoring was initiated, and anesthesia was induced with propofol and maintained with sevoflurane in 50% oxygen/air, with an adjuvant infusion of remifentanil to maintain intraoperative bispectral index values (40–60) and hemodynamic stability.
After induction, headphones were placed on each patient. The classical music selected by the investigator was started in group M patients with an individual comfortable volume. Preoperatively, each patient was asked to choose a comfortable sound volume. The sound was maintained throughout the surgical procedure. Likewise, headphones were also placed on patients in group C, but the player was not started. Approximately 30 minutes before the completion of surgery, ketorolac and ramosetron were administered for postoperative pain and nausea control, respectively. All anesthetics, including sevoflurane, were discontinued at the end of the surgery, and residual neuromuscular blocking was reversed. Tracheal extubation was performed, and the patient was transferred to the postanesthetic recovery unit (PACU).
In the PACU, postoperative pain was assessed using a numeric rating scale (NRS, 0–10) at 30 minutes. At 3, 24, and 36 hours postoperatively, the pain score was also assessed using NRS in the ward. Rescue analgesics (fentanyl 50 µg) were administered when the NRS score was > 4 or patients requested. The incidence of nausea and vomiting was measured at 30 minutes and 3, 24, and 36 hours after surgery, and a rescue drug, metoclopramide 10 mg, was administered, if needed. An anesthesiologist who was blinded to the study protocol estimated the overall data.
At 24 hours postoperatively, QoR-40 was surveyed by an anesthesiologist who was not assigned to the patient group. The questionnaire contained a total of 40 items regarding the quality of recovery that were classified into 5 dimensions, namely, emotion, physical comfort, psychological support, physical independence, and pain, comprising 9, 12, 7, 5, and 7 items, respectively. Each item was rated on a 5-point scale, with the sum scores ranging from 40 (poor quality of recovery) to 200 (excellent quality of recovery).
Publication 2023
Analgesics Anesthesia Anesthesiologist Anesthetics Clinical Protocols Drug Abuse Emotions Ethanol Ethics Committees, Research Fentanyl Gynecologic Surgical Procedures Hearing Impairment Hemodynamics Ketorolac Laparoscopy Memory Disorders Metoclopramide Nausea Operative Surgical Procedures Oxygen Pain Pain, Postoperative Patients Pharmaceutical Adjuvants Pharmaceutical Preparations Physical Examination Premedication Propofol ramosetron Remifentanil Sevoflurane Sound Surgical Procedures, Laparoscopic Tracheal Extubation
The study was reported according to CONSORT statement. Eligibility criteria for this study were patients aged between 40 and 80 years who were diagnosed with primary osteoarthritis of the knee scheduled to undergo unilateral TKA. The exclusion criteria were (i) severe deformity that required stem or metal augmentation, (ii) previous knee surgery, (iii) allergy to the drug used in the study, (iv) chronic kidney disease (estimated glomerular filtration rate < 60 mL/min), (v) liver cirrhosis, and (vi) refusal to participate. The patients were blinded to the intervention and randomly assigned into 2 groups: epinephrine (EN) and control (C) groups. A block-of-4 randomized sequence was generated using www.randomization.com and concealed by opaque envelopes. The process was done by a research coordinator who was not involved in the study. The flow of patients in this study is summarized in Figure 1.
3 experienced arthroplasty surgeons (RN, KC, and CP) performed all the procedures with the same surgical techniques. All operations were carried out under spinal anesthesia and adductor canal block. A tourniquet pressure of 300 mmHg was inflated before skin incision and deflated after skin closure. A mini-medial parapatellar approach was used (5 (link)). The neutral mechanical axis of the lower limb was restored. After trial components removal, a scrub nurse, who did not take part in the study, opened the concealed envelope and assigned the patients to the allocated treatment.
LIA, including 20 mL 0.5% bupivacaine, 30 mg ketorolac, and 0.6 mg epinephrine (1:1000) was used in the EN group while in the C group similar ingredients without epinephrine were used. LIA in each group was diluted with normal saline until the total volume was 100 mL. The surgeon was blinded to the intervention and injected LIA into 4 areas (25 mL per area); (i) posterior, posteromedial and posterolateral capsules, (ii) medial gutter, (iii) lateral gutter, and (iv) quadriceps muscles, retinacular tissue, pes anserinus, suprapatellar and infrapatellar fat pads (6 (link)). Cemented Nexgen LPS-Flex fixed bearing prostheses (Zimmer, Warsaw, IN, USA) were implanted without patellar resurfacing. A vacuum drain was placed intra-articularly and retained for 48 hours after surgery. The same rehabilitative program was started on the 1st postoperative day. For postoperative pain management until 48 hours after surgery, all patients received intravenous parecoxib (40 mg) every 12 hours and oral acetaminophen with codeine (300/15 mg) every 6 hours. Intravenous morphine (2 mg) every 2 hours was given as a rescue drug. All patients and outcome assessors were blinded to the intervention. Postoperative visual analog pain score (VAPS, ranging from 0 [no pain] to 10 [extreme pain]) and morphine consumption were recorded every 6 hours until 48 hours after TKA. Before discharge, postoperative range of motion (ROM) and complications including infection, skin necrosis, and wound complication were also recorded.
Publication 2023
A 300 acetaminophen - codeine Arthroplasty Bupivacaine Capsule Cardiac Arrest Chronic Kidney Diseases Congenital Abnormality Drug Allergy Eligibility Determination Epinephrine Epistropheus Glomerular Filtration Rate Infection Ketorolac Knee Liver Cirrhosis Lower Extremity Metals Morphine Necrosis Normal Saline Nurses Operative Surgical Procedures Osteoarthritis, Knee Pad, Fat Pain Pain, Postoperative parecoxib Patella Patient Discharge Patients Pressure Prosthesis Pulp Canals Quadriceps Femoris Rehabilitation Skin Spinal Anesthesia Stem, Plant Surgeons Tissues Tourniquets Vacuum Wounds
Patients older than 18 years were considered eligible for enrollment if they had experienced chest discomfort lasting more than 20 min and had been diagnosed with acute STEMI based on clinical, laboratory, and electrocardiographic (ECG) findings and are eligible for undergoing primary PCI within 90 min of admission and within 12 h of symptom onset. The definition of acute STEMI according to the European Society of Cardiology Guidelines is a persistent chest discomfort with the elevation of at least one cardiac troponin value above the 99th percentile upper limit and ST-segment elevation in at least 2 contiguous leads (Ibanez et al. 2018 (link)). The exclusion criteria are listed in Table 1.

Exclusion criteria of the study; PCI percutaneous coronary intervention

Patients unwilling to participate
Symptoms for more than 12 h
Presence of cardiogenic shock (Killip Class IV)
Cardiopulmonary resuscitation before transition to catheterization laboratory
History of cardiac transplantation
History of PCI or coronary artery bypass graft surgery in the last month
Patients who received thrombolytic before admission to our center
Current use of pentoxifylline for another indication
Use of ketorolac in the last 24 h
Publication 2023
Cardiopulmonary Resuscitation Cardiovascular System Catheterizations, Cardiac Chest Clinical Laboratory Services Coronary Artery Bypass Surgery Electrocardiography Europeans Fibrinolytic Agents Heart Ketorolac Patients Pentoxifylline Shock, Cardiogenic ST Segment Elevation Myocardial Infarction Troponin
Male Fos2A-iCreER mice (TRAP2) (Jax 030323) and adult male and female C57/BL6 mice (16–24 weeks old) were purchased from The Jackson Laboratory. Mice were housed in a temperature-controlled vivarium on a 12-hour light/12-hour dark cycle (lights on at 0700 hours; lights off at 1900 hours) with ad libitum access to food and water. CD1 male mice (16–26 weeks old,) and male SD rats (10–14 weeks old) were also purchased from The Jackson Laboratory and Charles River Laboratories, respectively. For carbamazepine, oral gavage of carbamazepine (Novartis, packaged by Precision Dose) at 60 mg/kg was used. For ketorolac (Hospira), oral gavage of 10 mg/kg was used. For tamoxifen (MilliporeSigma, WXBD4583V), intraperitoneal injection of 150 mg/kg dissolved in corn oil was used.
Full text: Click here
Publication 2023
Adult Carbamazepine Corn oil Females Food Injections, Intraperitoneal Ketorolac Light Males Mice, House Rattus Rivers Tamoxifen Tube Feeding

Top products related to «Ketorolac»

Sourced in United States, Italy
Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) used as a laboratory reagent. It functions as an inhibitor of cyclooxygenase enzymes, thereby reducing the production of prostaglandins.
Sourced in United States, Germany, United Kingdom, Brazil, Italy, Sao Tome and Principe, China, India, Japan, Denmark, Australia, Macao, Spain, France, New Zealand, Poland, Singapore, Switzerland, Belgium, Canada, Argentina, Czechia, Hungary
Indomethacin is a laboratory reagent used in various research applications. It is a non-steroidal anti-inflammatory drug (NSAID) that inhibits the production of prostaglandins, which are involved in inflammation and pain. Indomethacin can be used to study the role of prostaglandins in biological processes.
Sourced in Panama, United States
The Infusion Harness is a device used to secure intravenous (IV) lines and other medical tubing during patient care. It is designed to hold and manage the placement of these lines, ensuring they remain in the desired position and prevent unintended movement or dislodgement.
Sourced in United States, Sao Tome and Principe, Macao
Ketamine is a dissociative anesthetic used in veterinary medicine. It is a Schedule III controlled substance in the United States. Ketamine is commonly used for the induction and maintenance of general anesthesia in animals.
Sourced in United States, China, Germany, Japan, Canada, United Kingdom, France, Italy, Morocco, Sweden
Male Sprague-Dawley rats are a widely used laboratory animal model. They are characterized by their large size, docile temperament, and well-established physiological and behavioral characteristics. These rats are commonly used in a variety of research applications.
Sourced in United States
Methohexital sodium is a laboratory chemical used as a sedative and anesthetic agent. It is a white, crystalline powder that is soluble in water and alcohol. Methohexital sodium is used in research and clinical settings to induce general anesthesia or conscious sedation in animals and humans.
Sourced in United States
Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) used in the laboratory setting. It functions as a potent analgesic and anti-inflammatory agent.
Sourced in Germany, France, United States, United Kingdom, Canada, Italy, Brazil, Belgium, Cameroon, Switzerland, Spain, Australia, Ireland, Sweden, Portugal, Netherlands, Austria, Denmark, New Zealand
Rompun is a veterinary drug used as a sedative and analgesic for animals. It contains the active ingredient xylazine hydrochloride. Rompun is designed to induce a state of sedation and pain relief in animals during medical procedures or transportation.
Sourced in United States, Germany, United Kingdom, France, Italy, Switzerland, Czechia, Sweden, Mexico
Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) that is used as a pain reliever and anti-inflammatory agent. It is a commonly used pharmaceutical ingredient in various lab equipment and medical products.
Sourced in Ireland, United States
Ketorolac tris salt is a chemical compound used in laboratory settings. It is a white crystalline powder that serves as a key component in various research and analytical applications. The core function of ketorolac tris salt is to act as a starting material or intermediate in the synthesis of other compounds or the development of analytical methods. Its specific applications and intended uses are not provided within the scope of this factual and unbiased description.

More about "Ketorolac"

Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that is widely used to manage moderate to severe pain, including postoperative pain, cancer pain, and pain associated with musculoskeletal conditions.
This versatile medication works by inhibiting the cyclooxygenase (COX) enzymes, which are involved in the production of prostaglandins that contribute to inflammation and pain.
Ketorolac is available in various formulations, including oral, parenteral, and topical, and its efficacy and safety have been extensively studied.
Researchers can optimize their Ketorolac studies using PubCompare.ai, an AI-driven platform that helps identify the best protocols and products from the literature, pre-prints, and patents, while providing detailed comparisons to enhance reproducibility and accuracy.
In addition to Ketorolac, other NSAIDs like Indomethacin, Diclofenac, and Ibuprofen may also be used to manage pain and inflammation.
Ketamine, a dissociative anesthetic, is sometimes used in conjunction with Ketorolac for pain management, particularly in postoperative settings.
Methohexital sodium and Rompun (xylazine) are also commonly used in animal studies involving Ketorolac, such as those conducted on Male Sprague-Dawley rats.
By utilizing the insights gained from the MeSH term description and Metadescription, researchers can optimize their Ketorolac studies and ensure the reproducibility and accuracy of their findings.
PubCompare.ai's powerful tools can be a valuable resource in this endeavor.